Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). (Q34610252)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

title

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

main subject

phase II clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

cetuximab

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

author name string

Julen Fernandez-Plana

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

Carlos Pericay

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

Guillermo Quintero

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

Vicente Alonso

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

Antonieta Salud

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

Miguel Mendez

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

Mercedes Salgado

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

Eugeni Saigi

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

Luis Cirera

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

ACROSS Study Group

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

language of work or name

English

0 references

publication date

22 November 2014

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

published in

BMC Cancer

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

volume

14

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

page(s)

865

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

cites work

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Colorectal metastasis (liver and lung).

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

7 July 2018

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1186%2F1471-2407-14-865

retrieved

21 January 2018

Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1186%2F1471-2407-14-865

retrieved

21 January 2018

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1186%2F1471-2407-14-865

retrieved

21 January 2018

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251687

retrieved

26 October 2018

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25417182

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/1471-2407-14-865

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

Dimensions Publication ID

1001553284

0 references

PMC publication ID

4251687

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

PubMed publication ID

25417182

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25417182

retrieved

3 August 2017

ResearchGate publication ID

268789168

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34610252&oldid=2196860030"